Two clinical trials with the anti-HER1 MAbs cetuximab and panitumumab, failed in augmenting the effect of radiotherapy plus high-dose cisplatin in SCCHN patients with stage III/IV tumors (79, 80). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.